Moderna, Inc. (NASDAQ:MRNA) Expected to Post Earnings of $4.72 Per Share

Analysts expect Moderna, Inc. (NASDAQ:MRNAGet Rating) to report earnings of $4.72 per share for the current quarter, according to Zacks. Seven analysts have issued estimates for Moderna’s earnings, with estimates ranging from $2.02 to $5.88. Moderna posted earnings per share of $6.46 in the same quarter last year, which suggests a negative year over year growth rate of 26.9%. The business is scheduled to issue its next earnings results on Monday, January 1st.

Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Moderna.

Moderna (NASDAQ:MRNAGet Rating) last posted its quarterly earnings data on Wednesday, May 4th. The company reported $8.58 EPS for the quarter, topping the consensus estimate of $6.16 by $2.42. The firm had revenue of $6.07 billion during the quarter, compared to analyst estimates of $4.43 billion. Moderna had a net margin of 64.77% and a return on equity of 121.86%. Moderna’s revenue was up 213.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.84 EPS.

A number of analysts recently issued reports on the stock. SVB Leerink lowered their price target on shares of Moderna from $81.00 to $80.00 and set an “underperform” rating on the stock in a report on Friday, March 25th. Bank of America upgraded shares of Moderna from an “underperform” rating to a “neutral” rating and increased their target price for the company from $135.00 to $180.00 in a research report on Friday, January 21st. Barclays dropped their price objective on shares of Moderna from $404.00 to $210.00 in a report on Friday, February 25th. Jefferies Financial Group lowered their target price on shares of Moderna from $200.00 to $170.00 in a research note on Friday, February 25th. Finally, Morgan Stanley increased their target price on shares of Moderna from $205.00 to $217.00 and gave the stock an “equal weight” rating in a research note on Tuesday, April 12th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $246.92.

MRNA stock opened at $137.91 on Wednesday. The firm’s fifty day simple moving average is $155.48 and its 200-day simple moving average is $201.21. The company has a market capitalization of $54.86 billion, a P/E ratio of 4.05, a price-to-earnings-growth ratio of 0.75 and a beta of 1.70. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.77 and a quick ratio of 1.56. Moderna has a 12 month low of $119.01 and a 12 month high of $497.49.

In related news, President Stephen Hoge sold 20,000 shares of the firm’s stock in a transaction on Monday, February 14th. The stock was sold at an average price of $157.71, for a total transaction of $3,154,200.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Noubar Afeyan sold 100,000 shares of the firm’s stock in a transaction on Friday, May 13th. The stock was sold at an average price of $134.47, for a total value of $13,447,000.00. Following the transaction, the director now owns 5,816,657 shares in the company, valued at $782,165,866.79. The disclosure for this sale can be found here. Insiders have sold 308,126 shares of company stock valued at $46,000,674 in the last three months. Corporate insiders own 17.30% of the company’s stock.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. SVB Wealth LLC lifted its stake in Moderna by 12.3% during the first quarter. SVB Wealth LLC now owns 1,501 shares of the company’s stock worth $258,000 after purchasing an additional 164 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Moderna by 108.2% during the first quarter. Renaissance Technologies LLC now owns 3,818,180 shares of the company’s stock worth $657,720,000 after purchasing an additional 1,984,458 shares during the last quarter. Ontario Teachers Pension Plan Board lifted its stake in Moderna by 60.4% during the first quarter. Ontario Teachers Pension Plan Board now owns 11,513 shares of the company’s stock worth $1,983,000 after purchasing an additional 4,337 shares during the last quarter. Northern Trust Corp lifted its stake in Moderna by 0.6% during the first quarter. Northern Trust Corp now owns 3,503,325 shares of the company’s stock worth $603,483,000 after purchasing an additional 20,416 shares during the last quarter. Finally, ING Groep NV lifted its stake in Moderna by 25.5% in the first quarter. ING Groep NV now owns 79,370 shares of the company’s stock valued at $13,672,000 after buying an additional 16,106 shares during the last quarter. Hedge funds and other institutional investors own 61.20% of the company’s stock.

About Moderna (Get Rating)

Moderna, Inc, a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States and internationally. The company has 44 development programs, which includes 26 in clinical trials across seven modalities comprising prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic intracellular therapeutics, and inhaled pulmonary therapeutics.

See Also

Get a free copy of the Zacks research report on Moderna (MRNA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Moderna (NASDAQ:MRNA)

Receive News & Ratings for Moderna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Moderna and related companies with MarketBeat.com's FREE daily email newsletter.